GLUE — Monte Rosa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $284.34m
- $51.93m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -7.74 | -35.9 | -74 | -109 | -135 |
Depreciation | |||||
Non-Cash Items | -0.276 | 8.03 | 6.18 | 14.4 | 12.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.77 | 4.25 | 6.29 | -2.13 | 72.5 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -6.17 | -23.1 | -59.4 | -92.5 | -43.8 |
Capital Expenditures | -1.39 | -3.39 | -9.73 | -12.9 | -19 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.079 | -206 | 108 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -1.39 | -3.39 | -9.65 | -219 | 88.8 |
Financing Cash Flow Items | 0 | -0.44 | -3.34 | -0.364 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 15 | 60.1 | 378 | 20.5 | 27.5 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.44 | 33.6 | 309 | -291 | 72.5 |